Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0APGYS |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-EGFR/TROP2 bsAb |
|||||
| Antigen Name | EGFR; TROP2 |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
DM001 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key inclusion criteria: signed consent; age ≥18; ECOG 0-1; metastatic breast cancer/EGFRmut or EGFRwt NSCLC/gastric/CRC refractory to standard therapy; measurable disease (RECIST 1.1); life expectancy ≥3 months.
|
||||
| Administration Dosage |
Subjects may continue to receive DM001 (with an increased dose that has been assessed as safe in the dose-escalation period) once every 3 weeks (Q3W) for a total of 6 cycles at the discretion of the investigators, until unacceptable toxicity, progressive disease (PD), or withdrawal of consent.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06475937 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM001 in Patients with Advanced Solid Tumors
|
||||
| Primary Endpoint |
Primary endpoints include DLT incidence (grade 3 neurological/grade 4 toxicities) and MTD determination (dose with ≤1/6 DLTs) for DM001 over 12 months.
|
||||
| Other Endpoint |
Secondary endpoints comprise PK parameters (AUC0-inf, Cmax, Tmax, Ctrough) and ORR (CR+PR per RECIST 1.1), all evaluated over 12 months.
|
||||